A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC - LIVIGNO-1 | NYU Langone Health

A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC - LIVIGNO-1